| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Atomoxetine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Atomoxetine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | | Atomoxetine | hsa00071 | Fatty acid degradation | 2.52E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Atomoxetine | hsa00190 | Oxidative phosphorylation | 3.92E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Atomoxetine | hsa00220 | Arginine biosynthesis | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | | Atomoxetine | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.97E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | | | Atomoxetine | hsa00310 | Lysine degradation | 1.53E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | | Atomoxetine | hsa00500 | Starch and sucrose metabolism | 4.90E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Atomoxetine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Atomoxetine | hsa00562 | Inositol phosphate metabolism | 2.54E-03 | 4 | P27987, Q13572, Q96PE3, P42338 | ITPKB, ITPK1, INPP4A, PIK3CB | More | | | Atomoxetine | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Atomoxetine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | | Atomoxetine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.12E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Atomoxetine | hsa00730 | Thiamine metabolism | 1.21E-05 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | | Atomoxetine | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | | Atomoxetine | hsa00770 | Pantothenate and CoA biosynthesis | 5.15E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Atomoxetine | hsa00910 | Nitrogen metabolism | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | | Atomoxetine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.77E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Atomoxetine | hsa00983 | Drug metabolism - other enzymes | 2.46E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Atomoxetine | hsa01100 | Metabolic pathways | 3.52E-02 | 23 | P05089, O95455, P21953, P32320, P11766, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, Q08477, P15907, Q9UNP4, P37837, P32321, Q9BPW9, Q9UHY7, P43490, P46976, P06737 | ARG1, TGDS, BCKDHB, CDA, ADH5, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, CYP4F3, ST6GAL1, ST3GAL5, TALDO1, DCTD, DHRS9, ENOPH1, PBEF1, GYG1, PYGL | More | | | Atomoxetine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Atomoxetine | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | | Atomoxetine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | | Atomoxetine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | | Atomoxetine | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | | Atomoxetine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Atomoxetine | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | | Atomoxetine | hsa03013 | RNA transport | 7.94E-03 | 8 | P52298, O14893, P61326, Q7Z3B4, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, EIF3A, EIF3J, RPP38, TACC3 | More | | | Atomoxetine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Atomoxetine | hsa03040 | Spliceosome | 9.19E-06 | 10 | Q14562, O43143, O60508, Q99633, P08579, P26368, Q13595, Q01130, Q9UMS4, O43447 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, U2AF2, TRA2A, SFRS2, PRPF19, PPIH | More | | | Atomoxetine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | | Atomoxetine | hsa04014 | Ras signaling pathway | 3.62E-02 | 5 | P42338, P49767, P0DP23, P63218, P50151 | PIK3CB, VEGFC, CALM1, GNG5, GNG10 | More | | | Atomoxetine | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | | Atomoxetine | hsa04020 | Calcium signaling pathway | 2.42E-07 | 10 | P27987, P21796, Q16566, P17252, P30679, O15399, P25116, P0DP23, P23634, P49767 | ITPKB, VDAC1, CAMK4, PRKCA, GNA15, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | | Atomoxetine | hsa04024 | cAMP signaling pathway | 1.22E-03 | 6 | P42338, P0DP23, P23634, Q16566, O15399, P25116 | PIK3CB, CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | | Atomoxetine | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | | Atomoxetine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | | Atomoxetine | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | | Atomoxetine | hsa04064 | NF-kappa B signaling pathway | 1.68E-04 | 16 | P10415, P51617, O00463, Q13546, P14778, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, IRAK1, TRAF5, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | | Atomoxetine | hsa04070 | Phosphatidylinositol signaling system | 2.54E-04 | 8 | P0DP23, Q14643, P42338, Q96PE3, O14732, Q13572, P27987, P17252 | CALM1, ITPR1, PIK3CB, INPP4A, IMPA2, ITPK1, ITPKB, PRKCA | More | | | Atomoxetine | hsa04071 | Sphingolipid signaling pathway | 3.06E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | | Atomoxetine | hsa04072 | Phospholipase D signaling pathway | 5.17E-03 | 7 | P42338, Q92529, P43657, P25024, P25025, P19174, Q14344 | PIK3CB, SHC3, P2RY5, CXCR1, CXCR2, PLCG1, GNA13 | More | | | Atomoxetine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | | | Atomoxetine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Atomoxetine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | | Atomoxetine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Atomoxetine | hsa04145 | Phagosome | 1.32E-03 | 8 | P63261, Q15080, P14598, Q13509, P68371, Q13488, O60603, P27824 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, CANX | More | | | Atomoxetine | hsa04150 | mTOR signaling pathway | 2.23E-03 | 6 | P42338, Q02750, Q9NQL2, P51812, Q13322, P49841 | PIK3CB, MAP2K1, RRAGD, RPS6KA3, GRB10, GSK3B | More | | | Atomoxetine | hsa04151 | PI3K-Akt signaling pathway | 3.96E-02 | 8 | P43657, P09603, Q9GZP0, P63218, P50151, P13612, O15335, Q13751 | P2RY5, CSF1, PDGFD, GNG5, GNG10, ITGA4, CHAD, LAMB3 | More | | | Atomoxetine | hsa04210 | Apoptosis | 5.05E-03 | 10 | Q13315, P10415, O76075, P01375, Q9NR28, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, TNF, DIABLO, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | | | Atomoxetine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | | Atomoxetine | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | | Atomoxetine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.85E-03 | 9 | P07550, P22694, P18848, Q13362, Q16537, P0DP23, P17252, P10415, P20020 | ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | | Atomoxetine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | | Atomoxetine | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | | Atomoxetine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Atomoxetine | hsa04371 | Apelin signaling pathway | 7.45E-03 | 5 | P63218, P50151, Q13485, Q16566, P0DP23 | GNG5, GNG10, SMAD4, CAMK4, CALM1 | More | | | Atomoxetine | hsa04380 | Osteoclast differentiation | 4.80E-02 | 4 | P06239, P42338, P14778, Q8N149 | LCK, PIK3CB, IL1R1, LILRA2 | More | | | Atomoxetine | hsa04390 | Hippo signaling pathway | 2.11E-03 | 6 | P63261, Q13485, O15105, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, SMAD7, LEF1, SNAI2, BIRC3 | More | | | Atomoxetine | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | | Atomoxetine | hsa04512 | ECM-receptor interaction | 3.88E-03 | 5 | Q13751, P07359, P13612, P08514, O15335 | LAMB3, GP1BA, ITGA4, ITGA2B, CHAD | More | | | Atomoxetine | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | | Atomoxetine | hsa04530 | Tight junction | 4.35E-02 | 2 | P63261, Q92974 | ACTG1, ARHGEF2 | More | | | Atomoxetine | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | | Atomoxetine | hsa04610 | Complement and coagulation cascades | 9.49E-04 | 3 | P09871, P0C0L4, P20023 | C1S, C4A, CR2 | More | | | Atomoxetine | hsa04611 | Platelet activation | 5.13E-04 | 4 | P08514, Q15746, Q8WYR1, P07359 | ITGA2B, MYLK, PIK3R5, GP1BA | More | | | Atomoxetine | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Atomoxetine | hsa04613 | Neutrophil extracellular trap formation | 2.04E-04 | 18 | P17252, P16109, O60603, P08246, Q92769, P04908, Q6FI13, Q99878, Q93077, P33778, P68431, P14598, Q15080, P08514, P21462, P07359, O43315, Q16539 | PRKCA, SELP, TLR2, ELA2, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, H2AC14, HIST1H2AC, H2BC3, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, ITGA2B, FPR1, GP1BA, AQP9, MAPK14 | More | | | Atomoxetine | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | | Atomoxetine | hsa04621 | NOD-like receptor signaling pathway | 1.93E-02 | 8 | Q16539, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | | | Atomoxetine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | | Atomoxetine | hsa04640 | Hematopoietic cell lineage | 1.45E-03 | 10 | P07359, P08514, P14778, P27930, P11215, P20023, P25063, P07766, P01732, P09564 | GP1BA, ITGA2B, IL1R1, IL1R2, ITGAM, CR2, CD24, CD3E, CD8A, CD7 | More | | | Atomoxetine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.09E-07 | 15 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | | | Atomoxetine | hsa04657 | IL-17 signaling pathway | 7.78E-05 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | | Atomoxetine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | | Atomoxetine | hsa04659 | Th17 cell differentiation | 1.76E-04 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | | | Atomoxetine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | | Atomoxetine | hsa04662 | B cell receptor signaling pathway | 1.12E-04 | 7 | P49841, P42338, P20023, Q8WV28, P11912, P21854, Q8N149 | GSK3B, PIK3CB, CR2, BLNK, CD79A, CD72, LILRA2 | More | | | Atomoxetine | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | | Atomoxetine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.25E-03 | 7 | P07948, P42338, P23528, P49006, P06396, P14598, P17252 | LYN, PIK3CB, CFL1, MARCKSL1, GSN, NCF1, PRKCA | More | | | Atomoxetine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Atomoxetine | hsa04713 | Circadian entrainment | 8.43E-03 | 4 | O15399, P0DP23, P63218, P50151 | GRIN2D, CALM1, GNG5, GNG10 | More | | | Atomoxetine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Atomoxetine | hsa04720 | Long-term potentiation | 1.00E-06 | 8 | P17252, Q16566, P16298, P0DP23, P51812, O15399, Q02750, Q14643 | PRKCA, CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1, ITPR1 | More | | | Atomoxetine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Atomoxetine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Atomoxetine | hsa04724 | Glutamatergic synapse | 9.99E-04 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | | Atomoxetine | hsa04725 | Cholinergic synapse | 1.04E-03 | 8 | P22694, Q14643, P63218, P50151, P18848, Q16566, P42338, P10415 | PRKACB, ITPR1, GNG5, GNG10, ATF4, CAMK4, PIK3CB, BCL2 | More | | | Atomoxetine | hsa04726 | Serotonergic synapse | 1.52E-02 | 4 | P63218, P50151, P33260, P09917 | GNG5, GNG10, CYP2C18, ALOX5 | More | | | Atomoxetine | hsa04727 | GABAergic synapse | 2.33E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | | Atomoxetine | hsa04728 | Dopaminergic synapse | 4.47E-02 | 4 | P63218, P50151, P0DP23, O00327 | GNG5, GNG10, CALM1, ARNTL | More | | | Atomoxetine | hsa04730 | Long-term depression | 4.53E-03 | 2 | Q14344, P07948 | GNA13, LYN | More | | | Atomoxetine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.26E-04 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Atomoxetine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | | Atomoxetine | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | | Atomoxetine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Atomoxetine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | | Atomoxetine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | | Atomoxetine | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | | Atomoxetine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | | Atomoxetine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | | Atomoxetine | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | | Atomoxetine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | | Atomoxetine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Atomoxetine | hsa04925 | Aldosterone synthesis and secretion | 2.55E-05 | 6 | Q14643, P0DP23, P17252, Q16566, P20020, P23634 | ITPR1, CALM1, PRKCA, CAMK4, ATP2B1, ATP2B4 | More | | | Atomoxetine | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 8 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15 | More | | | Atomoxetine | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Atomoxetine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | | Atomoxetine | hsa04929 | GnRH secretion | 3.63E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | | Atomoxetine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | | Atomoxetine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Atomoxetine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | | Atomoxetine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Atomoxetine | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | | Atomoxetine | hsa04966 | Collecting duct acid secretion | 9.34E-04 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | | Atomoxetine | hsa04970 | Salivary secretion | 4.63E-05 | 8 | P07550, P22694, Q14643, P20020, P23634, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1, CAMP | More | | | Atomoxetine | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | | Atomoxetine | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | | Atomoxetine | hsa04973 | Carbohydrate digestion and absorption | 6.19E-05 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | | Atomoxetine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | | Atomoxetine | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | | Atomoxetine | hsa05010 | Alzheimer disease | 4.39E-02 | 6 | O15399, Q9NZJ5, Q13564, Q71U36, P09603, P21796 | GRIN2D, EIF2AK3, APPBP1, TUBA1A, CSF1, VDAC1 | More | | | Atomoxetine | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | | Atomoxetine | hsa05017 | Spinocerebellar ataxia | 5.94E-03 | 4 | Q8TB72, O15399, P42338, P21796 | PUM2, GRIN2D, PIK3CB, VDAC1 | More | | | Atomoxetine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Atomoxetine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Atomoxetine | hsa05031 | Amphetamine addiction | 1.61E-03 | 7 | O15399, P0DP23, Q16566, P22694, P18848, P17252, Q13547 | GRIN2D, CALM1, CAMK4, PRKACB, ATF4, PRKCA, HDAC1 | More | | | Atomoxetine | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | | | Atomoxetine | hsa05034 | Alcoholism | 3.62E-02 | 5 | O15399, Q16566, P0DP23, P63218, P50151 | GRIN2D, CAMK4, CALM1, GNG5, GNG10 | More | | | Atomoxetine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.80E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | | Atomoxetine | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | | Atomoxetine | hsa05133 | Pertussis | 3.42E-03 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | | Atomoxetine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Atomoxetine | hsa05140 | Leishmaniasis | 2.17E-06 | 12 | P13612, O75015, P14598, P42224, O60603, P25963, P01375, P29350, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, TLR2, NFKBIA, TNF, PTPN6, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | | Atomoxetine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Atomoxetine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | | Atomoxetine | hsa05146 | Amoebiasis | 4.18E-06 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | | Atomoxetine | hsa05150 | Staphylococcus aureus infection | 4.83E-02 | 2 | P09871, P16109 | C1S, SELP | More | | | Atomoxetine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Atomoxetine | hsa05163 | Human cytomegalovirus infection | 4.03E-03 | 11 | P42338, P01375, P63218, P50151, P0DP23, P49841, P14778, P25025, Q16539, O00463, P30101 | PIK3CB, TNF, GNG5, GNG10, CALM1, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5, PDIA3 | More | | | Atomoxetine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.44E-03 | 9 | P42338, P62879, P63218, P50151, P16298, Q02750, P07948, P0DP23, P0CG47 | PIK3CB, GNB2, GNG5, GNG10, PPP3CB, MAP2K1, LYN, CALM1, UBB | More | | | Atomoxetine | hsa05168 | Herpes simplex virus 1 infection | 2.31E-04 | 17 | Q9UKJ0, P25963, P01568, Q05823, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13489, Q13398, Q9HCX3, Q03923, P52738, O75820, Q9UDV6, P10415 | PILRB, NFKBIA, IFNA21, RNASEL, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF211, ZNF304, ZNF85, ZNF140, ZNF189, ZNF212, BCL2 | More | | | Atomoxetine | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | | Atomoxetine | hsa05170 | Human immunodeficiency virus 1 infection | 1.63E-05 | 19 | P42338, Q02750, P62879, P63218, P50151, P16298, P0DP23, Q05397, P17252, Q13546, P30101, Q14643, P51617, O60603, P23528, P09693, P10415, Q9Y6Q5, P20333 | PIK3CB, MAP2K1, GNB2, GNG5, GNG10, PPP3CB, CALM1, PTK2, PRKCA, RIPK1, PDIA3, ITPR1, IRAK1, TLR2, CFL1, CD3G, BCL2, AP1M2, TNFRSF1B | More | | | Atomoxetine | hsa05200 | Pathways in cancer | 1.51E-02 | 12 | Q9UJU2, P17252, P43246, Q13485, P14923, P10415, Q13489, P49767, P25116, P78417, P0DP23, P01568 | LEF1, PRKCA, MSH2, SMAD4, JUP, BCL2, BIRC3, VEGFC, F2R, GSTO1, CALM1, IFNA21 | More | | | Atomoxetine | hsa05202 | Transcriptional misregulation in cancer | 1.77E-02 | 11 | Q15532, Q13315, P14780, Q15744, Q16548, O15550, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, MMP9, CEBPE, BCL2A1, UTX, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | | Atomoxetine | hsa05204 | Chemical carcinogenesis | 4.62E-02 | 2 | P78417, P33260 | GSTO1, CYP2C18 | More | | | Atomoxetine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Atomoxetine | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | | Atomoxetine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | | Atomoxetine | hsa05214 | Glioma | 5.48E-05 | 6 | P0DP23, Q16566, P17252, P42338, P04637, P24522 | CALM1, CAMK4, PRKCA, PIK3CB, TP53, GADD45A | More | | | Atomoxetine | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Atomoxetine | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Atomoxetine | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | | Atomoxetine | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | | Atomoxetine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | | Atomoxetine | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | | Atomoxetine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | | Atomoxetine | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Atomoxetine | hsa05323 | Rheumatoid arthritis | 2.00E-02 | 3 | Q13488, P10747, O60603 | TCIRG1, CD28, TLR2 | More | | | Atomoxetine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Atomoxetine | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Atomoxetine | hsa05340 | Primary immunodeficiency | 2.93E-02 | 2 | P11912, Q8WV28 | CD79A, BLNK | More | | | Atomoxetine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | | Atomoxetine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | | Atomoxetine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | | Atomoxetine | hsa05418 | Fluid shear stress and atherosclerosis | 1.75E-04 | 12 | Q16539, P42338, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, PIK3CB, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | |
|
